Dr. Darren Feldman (@drdarrenfeldman) 's Twitter Profile
Dr. Darren Feldman

@drdarrenfeldman

Genitourinary medical oncologist specializing in testicular CA, extragonadal germ cell tumors and kidney CA @sloan_kettering. Views and tweets are my own.

ID: 750077526098186240

calendar_today04-07-2016 21:23:12

200 Tweet

1,1K Followers

352 Following

ANZUP (@anzuptrials) 's Twitter Profile Photo

Another exciting Plenary - Keynote Two. Chaired by Prof. Haryana Dhillon and Chun Loo Gan, this session features international speakers Andrea Apolo, M.D. Dr. Darren Feldman Alex Wyatt and Ananya Choudhury. Get ready for inspiring insights and thought-provoking discussions! #ANZUP23 #Plenary

Another exciting Plenary - Keynote Two. Chaired by <a href="/hagsie/">Prof. Haryana Dhillon</a> and <a href="/ChunLGan/">Chun Loo Gan</a>, this session features international speakers <a href="/apolo_andrea/">Andrea Apolo, M.D.</a> <a href="/DrDarrenFeldman/">Dr. Darren Feldman</a> <a href="/ResearchWyatt/">Alex Wyatt</a> and Ananya Choudhury. Get ready for inspiring insights and thought-provoking discussions! #ANZUP23 #Plenary
CA: A Cancer Journal for Clinicians (@cacancerjournal) 's Twitter Profile Photo

This article reviews contemporary evidence-based treatments for extracranial testicular germ cell tumor, the acute and chronic toxic effects that may result, and highlights recent advances and progress in the field. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… Dr. Darren Feldman Jack Gleeson

This article reviews contemporary evidence-based treatments for extracranial testicular germ cell tumor, the acute and chronic toxic effects that may result, and highlights recent advances and progress in the field.

acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

<a href="/DrDarrenFeldman/">Dr. Darren Feldman</a>
<a href="/jgleesonirl/">Jack Gleeson</a>
Dr. Darren Feldman (@drdarrenfeldman) 's Twitter Profile Photo

Right now, amazing clinician scientist, colleague and friend, Andrea Apollo, presenting positive results of the Alliance Ambassador Trial of adjuvant pembro vs observation following cystectomy in urothelial cancer. #GU24 Alliance for Clinical Trials in Oncology

Right now, amazing clinician scientist, colleague and friend, Andrea Apollo, presenting positive results of the Alliance Ambassador Trial of adjuvant pembro vs observation following cystectomy in urothelial cancer.  #GU24 <a href="/ALLIANCE_org/">Alliance for Clinical Trials in Oncology</a>
Scott Eggener (@uroegg) 's Twitter Profile Photo

If you take care of testicular cancer patients (or want to in the future), not going to find a more comprehensive review than this...... Dr. Darren Feldman Jack Gleeson Testicular cancer in 2023: Current status and recent progress acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

Dr. Darren Feldman (@drdarrenfeldman) 's Twitter Profile Photo

Star UrologyMSK fellow Dr. Fady Baky presenting a poster on the MSK experience with our NYS DOH approved CLIA certified serum miRNA assay in stage I testis cancer showing high accuracy for predicting viable non-teratomatous GCT. Rich Matulewicz DrBagrodia

Star <a href="/UrologyMSK/">UrologyMSK</a> fellow Dr. Fady Baky presenting a poster on the MSK experience with our NYS DOH approved CLIA certified serum miRNA assay in stage I testis cancer showing high accuracy for predicting viable non-teratomatous GCT.  <a href="/RichMatulewicz/">Rich Matulewicz</a> <a href="/AdityaBagrodia/">DrBagrodia</a>
CA: A Cancer Journal for Clinicians (@cacancerjournal) 's Twitter Profile Photo

Read our March/April issue! acsjournals.onlinelibrary.wiley.com/toc/15424863/2… In this issue: 🔹 Moffitt Cancer Center researchers on a case of dMMR/MSI-H gastric cancer 🔹 2023 ACS Research report of #CancerDisparities in the US 🔹 Testicular cancer in 2023 by Dr. Darren Feldman Jack Gleeson et al OncoAlert

Yüksel Ürün (@dryukselurun) 's Twitter Profile Photo

Cabozantinib combined with nivolumab in patients with metastatic non-clear cell renal cell carcinoma ⭕️The objective response rate (ORR) was 48% ⭕️Median progression-free survival was 13 months ⭕️Median overall survival was 28 months. ⭕️Comparable results with KEYNOTE-B61,

Cabozantinib combined with nivolumab in patients with metastatic non-clear cell renal cell carcinoma

⭕️The objective response rate (ORR) was 48%
⭕️Median progression-free survival was 13 months
⭕️Median overall survival was 28 months.
⭕️Comparable results with KEYNOTE-B61,
Enrique Grande (@drenriquegrande) 's Twitter Profile Photo

⚡️ On European Urology - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.

⚡️ On <a href="/EUplatinum/">European Urology</a> - Cabozantinib + nivolumab shows promising results in non–clear cell renal cell carcinoma. With a 48% response rate and median overall survival of 28 months, this combination offers a potential new treatment option. No new safety concerns were observed.
Jonathan Rosenberg MD (@drrosenbergmsk) 's Twitter Profile Photo

Great opportunity to be mentored by a tremendous team of superb clinicians in one of the strongest environments for translational an clinical research!

Matt Campbell MD, MS (@docmattcampbell) 's Twitter Profile Photo

Standing room only for GCT session. Happy to see the enthusiasm to review new data and trial landscape. Time to finish the mission in testes/GCT! Great talks by Axel Heidenreich, Nabil Adra and Dr. Darren Feldman #GU25

Standing room only for GCT session.  Happy to see the enthusiasm to review new data and trial landscape.  Time to finish the mission in testes/GCT! Great talks by Axel Heidenreich, <a href="/nabiladra/">Nabil Adra</a> and <a href="/DrDarrenFeldman/">Dr. Darren Feldman</a> #GU25
Patrizia Giannatempo (@giannatempopatr) 's Twitter Profile Photo

🎯Amazing session on testicular cancer! So exciting to see new therapeutic approaches on the horizon. ✨CAR T-cells, ADCs, and bispecifics targeting Claudin 6 – the future is bright! #ASCOGU25 Dr. Darren Feldman Nabil Adra Robert Huddart💙 UroFocus OncoDaily

🎯Amazing session on testicular cancer! So exciting to see new therapeutic approaches on the horizon. ✨CAR T-cells, ADCs, and bispecifics targeting Claudin 6 – the future is bright! #ASCOGU25 <a href="/DrDarrenFeldman/">Dr. Darren Feldman</a> <a href="/nabiladra/">Nabil Adra</a> <a href="/robert_huddart/">Robert Huddart💙</a> <a href="/urofocus/">UroFocus</a> <a href="/oncodaily/">OncoDaily</a>
UroToday.com (@urotoday) 's Twitter Profile Photo

#STARLITE2: Phase 2 study of nivolumab + 177lutetium-Labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients With Advanced #ccRCC. Presentation by Dr. Darren Feldman Memorial Sloan Kettering Cancer Center. Presentation by Julian Chavarriaga University of Toronto >

#STARLITE2: Phase 2 study of nivolumab + 177lutetium-Labeled Anti–Carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients With Advanced #ccRCC. Presentation by <a href="/DrDarrenFeldman/">Dr. Darren Feldman</a> <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a>. Presentation by <a href="/chavarriagaj/">Julian Chavarriaga</a> <a href="/UofT/">University of Toronto</a> &gt;
Testicular Cancer (@testescancer) 's Twitter Profile Photo

Just 77 days away until our 10th annual Testicular Cancer Conference presented by Fennec Pharmaceuticals We are incredibly grateful to have Dr. Darren Feldman as our honorary speaker! Don’t wait, register today! …sticularcancerawarenessfoundation.org/tc-conference-… #testicularcancer #urology #menshealth

Just 77 days away until our 10th annual Testicular Cancer Conference presented by <a href="/FennecPharma/">Fennec Pharmaceuticals</a> 

We are incredibly grateful to have <a href="/DrDarrenFeldman/">Dr. Darren Feldman</a> as our honorary speaker! 

Don’t wait, register today! …sticularcancerawarenessfoundation.org/tc-conference-…

#testicularcancer #urology #menshealth